Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078421 | 0.82 | MAP2K1 (0.51) | PKMCYP3A4P2RY6P2RY14POLB | |
| SCHEMBL1038071 | 0.78 | MAP2K1 (0.45) | PKMKMT2AMEN1CTDSP1ACLY | |
| SCHEMBL1343591 | 0.75 | KMT2A (0.46) | KMT2AMEN1CTDSP1METAP2ACLY | |
| Hydrochloric Acid SCHEMBL3971455 | 0.74 | KMT2A (0.45) | KMT2AMEN1CTDSP1METAP2ACLY | |
| SCHEMBL3861492 | 0.73 | NR4A2 (0.40) | PKMKMT2AMEN1CTDSP1L3MBTL1 | |
| SCHEMBL1342083 | 0.71 | MAP2K1 (0.53) | KMT2AMEN1CTDSP1METAP2L3MBTL1 | |
| SCHEMBL4916674 | 0.71 | MAPT (0.50) | HDAC6ACLYAPEX1RAB9ASMN1; SMN2 | |
| SCHEMBL18272624 | 0.70 | MAP2K1 (0.49) | PKMKMT2AMEN1CTDSP1HDAC6 | |
| SCHEMBL687133 | 0.70 | KDM4E (0.48) | KMT2ACTDSP1HDAC6CYP3A4APEX1 | |
| SCHEMBL6016776 | 0.69 | EGFR (0.41) | FBP1EPHB2MKNK1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000810-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-1663210-B1 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-3000810-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | Array Biopharma, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2275102-B1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8513293-B2 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2130536-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2130537-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | ARRAY BIOPHARMA INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8193231-B2 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193229-B2 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-1874768-A | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2006-12-06 | — | — | CN | disclosed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| CN-1652776-A | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2005-08-10 | — | — | CN | disclosed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | PCNA, MKI67, HRAS | FBP1 1065/4885EPHB2 3715/4885MKNK1 2235/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | FBP1 2062/4885EPHB2 2092/4885MKNK1 380/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | FBP1 3301/4885EPHB2 2043/4885MKNK1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.